Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCC

Jacob Gadwa,Maria Amann,Thomas E Bickett,Michael W Knitz,Laurel B Darragh,Miles Piper,Benjamin Van Court,Sanjana Bukkapatnam,Tiffany T Pham,Xiao-Jing Wang,Anthony J Saviola,Laura Codarri Deak,Pablo Umaña,Christian Klein,Angelo D'Alessandro,Sana D Karam
DOI: https://doi.org/10.1016/j.xcrm.2023.101150
2023-08-15
Abstract:The implementation of cancer immunotherapies has seen limited clinical success in head and neck squamous cell carcinoma (HNSCC). Interleukin-2 (IL-2), which modulates the survival and functionality of lymphocytes, is an attractive target for new immunotherapies but one that is limited by presence of regulatory T cells (Tregs) expressing the high-affinity IL-2Rα. The bispecific immunocytokine PD1-IL2v preferentially delivers IL-2 signaling through IL-2Rβγ on PD-1-expressing cells. Selectively targeting the intermediate-affinity IL-2Rβγ can be leveraged to induce anti-tumor immune responses in effector T cells and natural killer (NK) cells while limiting the negative regulation of IL-2Rα activation on Tregs. Using radiation therapy (RT) in combination with PD1-IL2v improves local tumor control and survival, and controls metastatic spread in orthotopic HNSCC tumor models. PD1-IL2v drives systemic activation and expansion of circulating and tumor-infiltrating cytotoxic T cells and NK cells while limiting Treg-mediated immunosuppression. These data show that PD1-L2v induces durable systemic tumor control in HNSCC.
What problem does this paper attempt to address?